• 中国科学论文统计源期刊
  • 中国科技核心期刊
  • 美国化学文摘(CA)来源期刊
  • 日本科学技术振兴机构数据库(JST)

临床输血与检验 ›› 2022, Vol. 24 ›› Issue (1): 22-28.DOI: 10.3969/j.issn.1671-2587.2022.01.005

• 论著 • 上一篇    下一篇

利用CRISPR/Cas9技术敲除K562细胞中的SMIM1基因*

杨佳璇, 李明浩, 李艾静, 叶璐夷   

  1. 200051 上海市血液中心 输血研究所 分子免疫血液学学科
  • 收稿日期:2021-10-18 发布日期:2022-01-27
  • 通讯作者: 叶璐夷,女,副研究员,主要从事免疫血液学研究, (E-mail)yeluyi@sbc.org.cn。
  • 作者简介:杨佳璇(1994-),女,山东肥城人,研究实习员,硕士,主要从事免疫血液学研究,(E-mail)yangjiaxuan@sbc.org.cn。
  • 基金资助:
    *本课题受上海市血液中心科技基金(No.05J2002-09),国家自然科学基金面上项目(No.81970168),上海市公卫三年行动计划项目(No.GWV-3.6)资助

To Knock Out the SMIM1 Gene in K562 Cells by CRISPR/Cas9

YANG Jia-xuan, LI Ming-hao, LI Ai-jing, et al   

  1. Shanghai Blood Center 200051
  • Received:2021-10-18 Published:2022-01-27

摘要: 目的 利用慢病毒介导的CRISPR/Cas9基因编辑技术,在K562细胞系中敲除编码Vel血型抗原的SMIM1基因。方法 设计5条sgRNA序列,构建Cas9-sgRNA共表达质粒,在293T细胞中初步筛选切割效率较高的sgRNA序列。将筛选后的sgRNA通过第二代慢病毒包装系统包装慢病毒并感染K562细胞,提取细胞基因组DNA,进行Sanger测序和TA克隆检测。结果 使用易转染的293T细胞建立sgRNA的初步筛选平台,筛选出切割效率较高的sgRNA4序列。CRISPR/Cas9系统成功在K562细胞中SMIM1基因的sgRNA4识别位点发挥基因编辑活性。结论 证实了利用CRISPR/Cas9技术在K562细胞中敲除SMIM1基因的可行性,为构建Vel抗原表型阴性的细胞模型奠定基础,也为后续编辑其他血型抗原的基因提供实验依据。

关键词: CRISPR/Cas9, Vel抗原, SMIM1基因, K562细胞系

Abstract: Objective To knock out the SMIM1 gene encoding the Vel blood group antigen in the K562 cell line by lentivirus-mediated CRISPR/Cas9 gene editing. Methods We designed five sgRNA sequences and constructed Cas9-sgRNA co-expression plasmids to initially screen sgRNA sequences with higher cutting efficiency in 293T cells. The sgRNA which had been screened out was packaged with the second-generation lentivirus packaging system and then infected K562 cells. We extracted the genomic DNA for Sanger sequencing and TA cloning detection. Results We established a preliminary screening platform for sgRNA using easy-to-transfect 293T cells, and screened out sgRNA4 sequences with higher cutting efficiency. The CRISPR/Cas9 system successfully exerted gene editing activity at the sgRNA4 recognition site of SMIM1 gene in K562 cells. Conclusion We confirmed the feasibility of using CRISPR/Cas9 technology to knock out the SMIM1 gene in K562 cells, which was a foundation for constructing a cell model with negative Vel antigen phenotype and providing experimental basis for subsequent editing genes of other blood group antigens.

Key words: CRISPR/Cas9, Vel blood group, SMIM1 gene, K562 cell line

中图分类号: